{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:04:34Z","timestamp":1791925474490,"version":"4.3.4"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.intimp.2025.114519","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:27:12Z","timestamp":1744129632000},"page":"114519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Exosomal PD-L1 in non-small cell lung Cancer: Implications for immune evasion and resistance to immunotherapy"],"prefix":"10.1016","volume":"155","author":[{"given":"Mojtaba","family":"Tarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa Akbari","family":"Oryani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Javid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Karimi-Shahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"14","key":"10.1016\/j.intimp.2025.114519_bb0010","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.114519_bb0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-year overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC-update from PACIFIC","volume":"15","author":"Gray","year":"2020","journal-title":"Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer."},{"issue":"2","key":"10.1016\/j.intimp.2025.114519_bb0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2025.114519_bb0025","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1002\/jcp.29671","article-title":"Role of tumor microenvironment in the regulation of PD-L1: a novel role in resistance to cancer immunotherapy","volume":"235","author":"Kalantari Khandani","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s13402-019-00456-w","article-title":"Recent advances in the clinical development of immune checkpoint blockade therapy","volume":"42","author":"Ghahremanloo","year":"2019","journal-title":"Cell. Oncol."},{"issue":"25","key":"10.1016\/j.intimp.2025.114519_bb0035","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung Cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001698","article-title":"Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1","volume":"9","author":"Yin","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.114519_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2006.09.001","article-title":"Circulating microparticles: pathophysiology and clinical implications","volume":"21","author":"Piccin","year":"2007","journal-title":"Blood Rev."},{"key":"10.1016\/j.intimp.2025.114519_bb0050","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","article-title":"Exosomes","volume":"88","author":"Pegtel","year":"2019","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-019-0991-5","article-title":"Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance","volume":"18","author":"Mashouri","year":"2019","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2025.114519_bb0060","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ncb3169","article-title":"Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver","volume":"17","author":"Costa-Silva","year":"2015","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114519_bb0065","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nm.2753","article-title":"Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET","volume":"18","author":"Peinado","year":"2012","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.114519_bb0070","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00109-013-1020-6","article-title":"Exosomes in tumor microenvironment influence cancer progression and metastasis","volume":"91","author":"Kahlert","year":"2013","journal-title":"J. Mol. Med. (Berl)"},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0075","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-019-1074-3","article-title":"The role of exosomal PD-L1 in tumor progression and immunotherapy","volume":"18","author":"Xie","year":"2019","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2025.114519_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of Exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2025.114519_bb0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","article-title":"The importance of exosomal PDL1 in tumour immune evasion","volume":"20","author":"Daassi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.114519_bb0090","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fimmu.2020.00604","article-title":"The biogenesis, biology, and clinical significance of Exosomal PD-L1 in Cancer","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114519_bb0095","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.114519_bb0100","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0105","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/intimm\/8.5.773","article-title":"Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes","volume":"8","author":"Nishimura","year":"1996","journal-title":"Int. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2025.114519_bb0110","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101047","article-title":"The role of exosomal PD-L1 in tumor immunotherapy","volume":"14","author":"Wang","year":"2021","journal-title":"Transl. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114519_bb0120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Annals of oncology\u202f: official journal of the European Society for Medical Oncology."},{"issue":"6332","key":"10.1016\/j.intimp.2025.114519_bb0125","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.intimp.2025.114519_bb0130","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"issue":"20","key":"10.1016\/j.intimp.2025.114519_bb0135","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in Cancer therapy: current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.intimp.2025.114519_bb0140","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/MCB.00319-13","article-title":"PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2","volume":"33","author":"Patsoukis","year":"2013","journal-title":"Mol. Cell. Biol."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2025.114519_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.intimp.2025.114519_bb0150","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036861","article-title":"Advances and challenges of first-line immunotherapy for non-small cell lung cancer: a review","volume":"103","author":"Guo","year":"2024","journal-title":"Medicine"},{"issue":"7528","key":"10.1016\/j.intimp.2025.114519_bb0155","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2025.114519_bb0160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.114519_bb0165","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Annals of oncology\u202f: official journal of the European Society for Medical Oncology."},{"issue":"10","key":"10.1016\/j.intimp.2025.114519_bb0170","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2025.114519_bb0175","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Annals of oncology\u202f: official journal of the European Society for Medical Oncology."},{"issue":"2","key":"10.1016\/j.intimp.2025.114519_bb0180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/cgt.2016.77","article-title":"Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal cancer","volume":"24","author":"Nedaeinia","year":"2017","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.114519_bb0185","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri3622","article-title":"Regulation of immune responses by extracellular vesicles","volume":"14","author":"Robbins","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114519_bb0190","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","article-title":"Extracellular vesicles in Cancer: cell-to-cell mediators of metastasis","volume":"30","author":"Becker","year":"2016","journal-title":"Cancer Cell"},{"issue":"Pt 24","key":"10.1016\/j.intimp.2025.114519_bb0195","first-page":"5553","article-title":"Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles","volume":"126","author":"Colombo","year":"2013","journal-title":"J. Cell Sci."},{"issue":"6","key":"10.1016\/j.intimp.2025.114519_bb0200","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","article-title":"Communication by extracellular vesicles: where we are and where we need to go","volume":"164","author":"Tkach","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0205","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2018.1490143","article-title":"Ultrafiltration and size exclusion chromatography combined with asymmetrical-flow field-flow fractionation for the isolation and characterisation of extracellular vesicles from urine","volume":"7","author":"Oeyen","year":"2018","journal-title":"Journal of extracellular vesicles."},{"issue":"18","key":"10.1016\/j.intimp.2025.114519_bb0210","article-title":"Granulocytic Myeloid-Derived Suppressor Cells Promote the Stemness of Colorectal Cancer Cells through Exosomal S100A9","volume":"6","author":"Wang","year":"2019","journal-title":"Advanced Science (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"2","key":"10.1016\/j.intimp.2025.114519_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2019.04.004","article-title":"Exosomes in cancer development, metastasis, and immunity","volume":"1871","author":"Zhang","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.114519_bb0220","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.biopha.2018.03.148","article-title":"Tumor-derived extracellular vesicles in angiogenesis","volume":"102","author":"Song","year":"2018","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12943-019-0995-1","article-title":"Effects of exosomes on pre-metastatic niche formation in tumors","volume":"18","author":"Guo","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0230","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.gendis.2023.01.026","article-title":"The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy","volume":"11","author":"Alam","year":"2024","journal-title":"Genes & diseases."},{"issue":"2","key":"10.1016\/j.intimp.2025.114519_bb0235","first-page":"457","article-title":"Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells","volume":"120","author":"Chalmin","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0240","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/febs.15558","article-title":"Exosomes as mediators of immune regulation and immunotherapy in cancer","volume":"288","author":"Kugeratski","year":"2021","journal-title":"FEBS J."},{"issue":"6","key":"10.1016\/j.intimp.2025.114519_bb0245","doi-asserted-by":"crossref","first-page":"723","DOI":"10.7150\/ijbs.19642","article-title":"Exosomes from melatonin treated Hepatocellularcarcinoma cells Alter the Immunosupression status through STAT3 pathway in macrophages","volume":"13","author":"Cheng","year":"2017","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0250","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hep.30607","article-title":"Endoplasmic reticulum stress causes liver Cancer cells to release Exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages","volume":"70","author":"Liu","year":"2019","journal-title":"Hepatology (Baltimore, Md)."},{"key":"10.1016\/j.intimp.2025.114519_bb0255","article-title":"Exosomes: a promising avenue for cancer diagnosis beyond treatment","volume":"12","author":"Wang","year":"2024","journal-title":"Frontiers in cell and developmental biology."},{"issue":"4","key":"10.1016\/j.intimp.2025.114519_bb0260","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/stem.2575","article-title":"Concise review: MSC-derived exosomes for cell-free therapy","volume":"35","author":"Phinney","year":"2017","journal-title":"Stem Cells"},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0265","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mt.2015.44","article-title":"Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications","volume":"23","author":"Rani","year":"2015","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.gpb.2015.02.001","article-title":"Exosome and Exosomal MicroRNA: trafficking, sorting, and function","volume":"13","author":"Zhang","year":"2015","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.intimp.2025.114519_bb0275","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","article-title":"Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles","volume":"30","author":"Colombo","year":"2014","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0280","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"Journal of extracellular vesicles."},{"issue":"7718","key":"10.1016\/j.intimp.2025.114519_bb0285","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"issue":"7670","key":"10.1016\/j.intimp.2025.114519_bb0290","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"issue":"7670","key":"10.1016\/j.intimp.2025.114519_bb0295","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.intimp.2025.114519_bb0300","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","article-title":"Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.114519_bb0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00018-017-2595-9","article-title":"Current knowledge on exosome biogenesis and release","volume":"75","author":"Hessvik","year":"2018","journal-title":"Cellular and molecular life sciences\u202f: CMLS."},{"key":"10.1016\/j.intimp.2025.114519_bb0310","doi-asserted-by":"crossref","unstructured":"Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 2010;12(1):19\u201330; sup pp 1\u201313.","DOI":"10.1038\/ncb2000"},{"issue":"8","key":"10.1016\/j.intimp.2025.114519_bb0315","first-page":"1","article-title":"Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer","volume":"51","author":"Kim","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.114519_bb0320","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2025.114519_bb0325","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.celrep.2018.06.066","article-title":"ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation","volume":"24","author":"Monypenny","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18132-0","article-title":"IFN\u03b3 induces PD-L1 overexpression by JAK2\/STAT1\/IRF-1 signaling in EBV-positive gastric carcinoma","volume":"7","author":"Moon","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.114519_bb0335","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fonc.2018.00386","article-title":"Tumor-intrinsic PD-L1 signaling in Cancer initiation, development and treatment: beyond immune evasion","volume":"8","author":"Dong","year":"2018","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0340","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2010","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0345","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/ijc.29519","article-title":"HIF-1 at the crossroads of hypoxia, inflammation, and cancer","volume":"138","author":"Balamurugan","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2025.114519_bb0350","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fonc.2020.00492","article-title":"5-FU-induced upregulation of Exosomal PD-L1 causes immunosuppression in advanced gastric Cancer patients","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2025.114519_bb0355","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1038\/s41388-020-1270-z","article-title":"p300\/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer","volume":"39","author":"Liu","year":"2020","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.intimp.2025.114519_bb0360","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","article-title":"Clinical significance of PD-L1(+) exosomes in plasma of head and neck Cancer patients","volume":"24","author":"Theodoraki","year":"2018","journal-title":"Clinical cancer research\u202f: an official journal of the American Association for Cancer Research."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0365","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1038\/s41467-021-25990-w","article-title":"A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0370","article-title":"Sulfisoxazole Elicits Robust Antitumour Immune Response along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1","volume":"vol. 9","author":"Shin","year":"2022","journal-title":"Advanced Science (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0375","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.7150\/thno.68864","article-title":"Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1","volume":"12","author":"Lee","year":"2022","journal-title":"Theranostics"},{"issue":"19","key":"10.1016\/j.intimp.2025.114519_bb0380","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1158\/0008-5472.CAN-12-0925","article-title":"Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression","volume":"72","author":"Bobrie","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0385","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymthe.2016.10.009","article-title":"Disruption of circulating extracellular vesicles as a novel therapeutic strategy against Cancer metastasis","volume":"25","author":"Nishida-Aoki","year":"2017","journal-title":"Molecular therapy\u202f: the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.intimp.2025.114519_bb0390","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2017.08.020","article-title":"Manumycin a suppresses exosome biogenesis and secretion via targeted inhibition of Ras\/Raf\/ERK1\/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells","volume":"408","author":"Datta","year":"2017","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0395","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1038\/s41598-018-26411-7","article-title":"High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: a drug repurposing strategy for advanced cancer","volume":"8","author":"Datta","year":"2018","journal-title":"Sci. Rep."},{"issue":"22","key":"10.1016\/j.intimp.2025.114519_bb0400","doi-asserted-by":"crossref","first-page":"20083","DOI":"10.1074\/jbc.M301642200","article-title":"Exosome release is regulated by a calcium-dependent mechanism in K562 cells","volume":"278","author":"Savina","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0405","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-9966-29-44","article-title":"Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy","volume":"29","author":"Spugnini","year":"2010","journal-title":"Journal of experimental & clinical cancer research\u202f: CR."},{"issue":"5867","key":"10.1016\/j.intimp.2025.114519_bb0410","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide triggers budding of exosome vesicles into multivesicular endosomes","volume":"319","author":"Trajkovic","year":"2008","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0415","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/s41467-019-09387-4","article-title":"Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor a","volume":"10","author":"Im","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0420","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12967-019-2101-2","article-title":"Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients","volume":"17","author":"Li","year":"2019","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.114519_bb0425","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.114519_bb0430","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","article-title":"Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma","volume":"17","author":"Frigola","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.114519_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of Exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2025.114519_bb0440","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","article-title":"Clinical significance of PD-L1+ exosomes in plasma of head and neck Cancer patients","volume":"24","author":"Theodoraki","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.114519_bb0445","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8839978","article-title":"Clinical implications of Exosomal PD-L1 in Cancer immunotherapy","volume":"2021","author":"Ayala-Mar","year":"2021","journal-title":"J Immunol Res"},{"issue":"7528","key":"10.1016\/j.intimp.2025.114519_bb0450","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.intimp.2025.114519_bb0455","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in stage III non\u2013small-cell lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.intimp.2025.114519_bb0460","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0465","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/s41467-019-09387-4","article-title":"Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor a","volume":"10","author":"Im","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2025.114519_bb0470","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0475","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","article-title":"Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation","volume":"23","author":"Guo","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.114519_bb0480","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fonc.2020.00760","article-title":"Anti-PD-1 therapy response predicted by the combination of Exosomal PD-L1 and CD28","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114519_bb0485","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/bjc.2018.9","article-title":"PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC","volume":"118","author":"Del Re","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.114519_bb0490","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/cei\/uxac045","article-title":"Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients","volume":"208","author":"Wang","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2025.114519_bb0495","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2019.09.013","article-title":"Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer","volume":"137","author":"Teramoto","year":"2019","journal-title":"Lung cancer (Amsterdam, Netherlands)."},{"issue":"10","key":"10.1016\/j.intimp.2025.114519_bb0500","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1349589","article-title":"A novel bifunctional anti-PD-L1\/TGF-\u03b2 trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells","volume":"6","author":"David","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0505","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","article-title":"Exosomes: key players in cancer and potential therapeutic strategy","volume":"5","author":"Dai","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.114519_bb0510","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006362","article-title":"Accumulation of T-cell-suppressive PD-L1<sup>high<\/sup> extracellular vesicles is associated with GvHD and might impact GvL efficacy","volume":"11","author":"Baur","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0515","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1038\/s41467-024-48200-9","article-title":"PD-1\/CD80+ small extracellular vesicles from immunocytes induce cold tumours featured with enhanced adaptive immunosuppression","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.intimp.2025.114519_bb0520","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcyt.2023.03.009","article-title":"Qualification of a multidonor mixed lymphocyte reaction assay for the functional characterization of immunomodulatory extracellular vesicles","volume":"25","author":"Bremer","year":"2023","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2020.05.008","article-title":"Clinical activity and safety of Atezolizumab in a phase 1 study of patients with relapsed\/refractory small-cell lung Cancer","volume":"21","author":"Chiang","year":"2020","journal-title":"Clin. Lung Cancer"},{"issue":"101","key":"10.1016\/j.intimp.2025.114519_bb0530","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2018.06.031","article-title":"Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study","author":"Horn","year":"2018","journal-title":"European journal of cancer (Oxford, England\u202f: 1990)"},{"issue":"24","key":"10.1016\/j.intimp.2025.114519_bb0535","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II trial of Atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1\u2013selected advanced non\u2013small-cell lung Cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10030","key":"10.1016\/j.intimp.2025.114519_bb0540","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet (London, England)."},{"issue":"24","key":"10.1016\/j.intimp.2025.114519_bb0545","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2025.114519_bb0550","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for Atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer."},{"issue":"22","key":"10.1016\/j.intimp.2025.114519_bb0555","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.19.03158","article-title":"Safety and patient-reported outcomes of Atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non-small-cell lung Cancer","volume":"38","author":"Reck","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2025.114519_bb0560","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer."},{"issue":"4","key":"10.1016\/j.intimp.2025.114519_bb0565","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer."},{"issue":"7","key":"10.1016\/j.intimp.2025.114519_bb0570","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2025.114519_bb0575","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/jco.2015.33.15_suppl.8034","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy","volume":"33","author":"Gulley","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2025.114519_bb0580","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS9105","article-title":"Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: the phase 3 JAVELIN lung 100 trial","volume":"34","author":"Reck","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2025.114519_bb0585","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/jco.2015.33.15_suppl.8032","article-title":"Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)","volume":"33","author":"Rizvi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114519_bb0590","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without Tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung Cancer: the MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114519_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2021.02.010","article-title":"Patient-reported outcomes with Durvalumab with or without Tremelimumab versus standard chemotherapy as first-line treatment of metastatic non-small-cell lung Cancer (MYSTIC)","volume":"22","author":"Garon","year":"2021","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.114519_bb0600","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2022.09.223","article-title":"NEPTUNE: phase 3 study of first-line Durvalumab plus Tremelimumab in patients with metastatic NSCLC","volume":"18","author":"De Castro","year":"2023","journal-title":"Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer."},{"issue":"2","key":"10.1016\/j.intimp.2025.114519_bb0605","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925005090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925005090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:36:41Z","timestamp":1778053001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925005090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":121,"alternative-id":["S1567576925005090"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114519","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exosomal PD-L1 in non-small cell lung Cancer: Implications for immune evasion and resistance to immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114519"}}